Edible mushrooms are well-known for their health and nutritional benefits, however, undesirable effects have been reported in animals fed with these types of edible mushrooms (Nieminen et al., 2009). For health and safety reason, it is necessary to evaluate the toxicity of edible mushrooms, especially those that have been artificially cultured in recent decades. The aim of this study was to assess the safety of the edible mushroom Agrocybe aegerita, which is also known as Agrocybe cylindracea in Europe and America. Components from A. aegerita (Yt) were extracted in water and unexpectedly displayed lethal effect and median lethal dose (LD50) at 8.77 g/kg. Strong hepatic toxicity in BALB/c mice was observed when mice were administered with 25 and 250 mg/kg body weight/day of Yt for 6 days. To identify the hepatotoxic components, Yt was further separated into two components by Diaion HP-20 column chromatography to produce the proteins (Yp) and small molecules (Ys) fractions. Biochemical and histopathological analysis showed that Yp could induce liver injury. LC-MS/MS analysis of Yp identified the main causative agent as AAL (A. aegerita lectin), which was shown to have similar hepatotoxicity in the Yt and Yp fractions. In addition, proteinase treatment assays indicated that AAL is resistant to the degradation by digestive enzymes. We have shown that the strong hepatic toxicity is due to a lectin in A. aegerita. This study suggests that correct consumption of A. aegerita can avoid human health risk and help us better understand its nutritional and medicinal value.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.toxicon.2014.08.066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences.
Mol Biol Rep
January 2025
Department of Pharmaceutical Sciences & Technology, BIT Mesra, Ranchi, 835215, India.
Background: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are associated with a multifactorial complicated aetiology that is often coexisting and has a strong and distinct connection with cardiovascular diseases (CVDs). In order to accomplish effective and appropriate therapeutic strategies, a deeper understanding of the bidirectional interaction between NAFLD patients, NAFLD patients with T2DM, and NAFLD patients with CVDs is required to control the concomitant rise in prevalence of these conditions worldwide. This article also aims to shed light on the epidemiology and mechanisms behind the relationship between T2DM, NAFLD and the related cardiovascular consequences.
View Article and Find Full Text PDFQuantification of Vascular Remodeling and Sinusoidal Capillarization to Assess Liver Fibrosis with Photoacoustic Imaging.
Radiology
January 2025
From the Department of Radiology, The Third Affiliated Hospital of Southern Medical University (Academy of Orthopedics, Guangdong Province), Guangzhou, China (W.L., L.S., R.Z., Y.Z.); and Medical Research Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Zhongshan 2nd Rd, Yuexiu District, Guangzhou 510000, People's Republic of China (J.L., H.L., X.Z., F.X., T.S., K.L., L.N.).
Background Photoacoustic microscopy (PAM) can be used to detect strong absorption from endogenous and exogenous contrast material, making it promising for detailed structural and functional imaging of hepatic sinusoids, including dynamic visualization of permeability. Purpose To evaluate whether PAM-based quantitative parameters of liver function and integrity (lacunarity, blood oxygen saturation [Sao], and Evans blue [EB] permeability) are associated with histopathologic indexes of fibrosis in a mouse model. Materials and Methods Between October 2022 and July 2023, a total of 35 male C57BL/6 mice were included in this study and received intraperitoneal injection of carbon tetrachloride to establish mouse models of progressive liver fibrosis, with seven mice in each group.
View Article and Find Full Text PDFinfection as a contributing factor to metabolic dysfunction-associated steatohepatitis: A population-based insight.
World J Hepatol
January 2025
Department of Cardiothoracic Surgery, Zhuji People's Hospital, Zhuji 311800, Zhejiang Province, China.
This letter discusses the research conducted by Abdel-Razeq , highlighting a significant association between () infection and metabolic dysfunction-associated steatohepatitis (MASH) in individuals with a prior history of infection. Using a comprehensive patient database, the study establishes an independent correlation between and an elevated risk of MASH, even after adjusting for coexisting conditions such as obesity, type 2 diabetes, and dyslipidemia. Notably, the findings suggest that may worsen liver pathology through inflammatory pathways, contributing to hepatic insulin resistance and lipid accumulation.
View Article and Find Full Text PDFNew advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024.
Acta Pharmacol Sin
January 2025
Department of Medical Microbiology & Parasitology, MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University Shanghai Medical College, Shanghai, 200032, China.
Metabolic dysfunction-associated steatotic liver disease (MASLD) covers a broad spectrum of profile from simple fatty liver, evolving to metabolic dysfunction-associated steatohepatitis (MASH), to hepatic fibrosis, further progressing to cirrhosis and hepatocellular carcinoma (HCC). MASLD has become a prevalent disease with 25% in average over the world. MASH is an active stage, and requires pharmacological intervention when there is necroptotic damage with fibrotic progression.
View Article and Find Full Text PDFMetabolic dysfunction-associated steatotic liver disease and type 2 diabetes: A dual threat to cardiac dysfunction progression.
World J Cardiol
January 2025
Chronic Disease and Health Management Research Center, Geriatric Hospital of Nanjing Medical University, Nanjing 210024, Jiangsu Province, China.
Metabolic dysfunction-associated steatotic liver disease (MASLD), particularly in patients with type 2 diabetes mellitus (T2DM), is increasingly recognized as a multi-system disease that affects both hepatic and cardiovascular health. This study explores the association between MASLD-related liver fibrosis and cardiac dysfunction, focusing on how liver fibrosis contributes to cardiac remodeling and dysfunction. Cernea 's research highlights the strong correlation between liver fibrosis and changes in left ventricular mass, left atrial dimensions, and systolic and diastolic function in diabetic patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!